Li Chen

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised c

J. Ji, J. Suo, Yingwei Xue, 2021, The Lancet. Oncology.

Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a multicenter prospective study.

Jun Liang, L. Shen, Y. Shu, 2012, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.

M. Aapro, Robert E. Smith, T. Ciuleanu, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a multicenter prospective study

Jun Liang, L. Shen, Y. Shu, 2012 .

A randomized, multicenter, controlled study to compare perioperative chemotherapy of oxaliplatin combined with TS-1 (SOX) versus SOX or oxaliplatin with capecitabine (XELOX) as post-operative chemotherapy in locally advanced gastric adenocarcinoma with D2 dissection (RESOLVE Trial).

J. Ji, Yingwei Xue, L. Shen, 2016 .